Aggregation of the high-affinity IgE receptor Fc(epsilon)RI on human monocytes and dendritic cells induces NF-kappaB activation.
In contrast to mast cells and basophils, the high-affinity IgE receptor (Fc(epsilon)RI) on monocytes and dendritic cells (DC), including epidermal Langerhans cells, is not constitutively expressed and lacks the beta-chain. Fc(epsilon)RI is upregulated on Langerhans cells of atopic individuals, particularly in atopic dermatitis skin. Although Fc(epsilon)RI provides IgE-mediated antigen focusing on monocytes and DC/Langerhans cells, its relevance for cell activation remains elusive, and the transcription factors regulating Fc(epsilon)RI-induced genes are unknown. We show that NF-kappaB, known to regulate genes essential for inflammatory responses and DC differentiation and function, is activated upon Fc(epsilon)RI ligation in primary human monocytes and DC. In Langerhans cells isolated from epidermis, NF-kappaB activation is restricted to donors expressing high Fc(epsilon)RI amounts. Fc(epsilon)RI-induced NF-kappaB complexes in monocytes and DC contain p50 and p65, but no other NF-kappaB subunits despite increased RelB expression during differentiation. NF-kappaB activation is preceded by serine phosphorylation and degradation of its inhibitory protein IkappaB-alpha without involving other IkappaB proteins. Finally, we show that Fc(epsilon)RI ligation on monocytes and DC leads to synthesis and release of tumor necrosis factor-alpha and monocyte chemoattractant protein-1, which is decreased by two mechanistically distinct inhibitors of NF-kappaB activation. Thus NF-kappaB activation represents a novel mechanism by which Fc(epsilon)RI on monocytes and DC potentially controls inflammatory reactions.
Kraft
Stefan
S
Department of Dermatology, Friedrich-Wilhelms-University, Bonn, Germany.
Novak
Natalija
N
Katoh
Norito
N
Bieber
Thomas
T
Rupec
Rudolf A
RA
D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology; D018932:Chemokine CCL2 / Q000378:metabolism; D003432:Cross-Linking Reagents / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000378:metabolism; D003713:Dendritic Cells / Q000378:metabolism*; D003876:Dermatitis, Atopic / Q000276:immunology / Q000378:metabolism*; D000078404:Epidermal Cells; D006801:Humans; D020672:I-kappa B Proteins; D007073:Immunoglobulin E / Q000276:immunology / Q000378:metabolism; D008024:Ligands; D009000:Monocytes / Q000378:metabolism*; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D010766:Phosphorylation; D017455:Receptors, IgE / Q000378:metabolism*; D012694:Serine / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000888:Antibodies, Anti-Idiotypic; D018932:Chemokine CCL2; D003432:Cross-Linking Reagents; D004268:DNA-Binding Proteins; D020672:I-kappa B Proteins; D008024:Ligands; D016328:NF-kappa B; C000606204:NFKBIA protein, human; D017455:Receptors, IgE; D014409:Tumor Necrosis Factor-alpha; C026408:anti-IgE antibodies; D000072000:NF-KappaB Inhibitor alpha; D007073:Immunoglobulin E; D012694:Serine